AI Insights

Global Artificial Intelligence (AI) in Clinical Trials Market

Published

5 hours ago

July 9, 2025

According to DelveInsight’s analysis, The demand for Artificial Intelligence in clinical trials is experiencing strong growth, primarily driven by the rising global prevalence of chronic conditions like diabetes, cardiovascular diseases, respiratory illnesses, and cancer. This growth is further supported by increased investments and funding dedicated to advancing drug discovery and development efforts. Additionally, the growing number of strategic collaborations and partnerships among pharmaceutical, biotechnology, and medical device companies is significantly boosting the adoption of AI-driven solutions in clinical trials. Together, these factors are anticipated to fuel the expansion of the AI in the clinical trials market during the forecast period from 2025 to 2032.

DelveInsight’s “Artificial Intelligence (AI) in Clinical Trials Market Insights, Competitive Landscape and Market Forecast-2032” report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Artificial Intelligence (AI) in Clinical Trials companies actively working in the market.

To know more about why North America is leading the market growth in the Artificial Intelligence (AI) in Clinical Trials market, get a snapshot of the report Artificial Intelligence (AI) in Clinical Trials Market Trends

https://www.delveinsight.com/sample-request/ai-in-clinical-trials-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Artificial Intelligence (AI) in Clinical Trials Overview

Artificial Intelligence (AI) in clinical trials refers to the use of advanced machine learning algorithms and data analytics to streamline and improve various aspects of clinical research. AI enhances trial design, patient recruitment, site selection, and data analysis by identifying patterns and predicting outcomes. It enables faster patient matching, optimizes protocol design, reduces trial timelines, and improves data quality and monitoring. AI also helps in real-time adverse event detection and adaptive trial management, making clinical trials more efficient, cost-effective, and patient-centric.

DelveInsight Analysis: The global Artificial Intelligence in clinical trials market size was valued at USD 1,350.79 million in 2024 and is projected to expand at a CAGR of 12.04% during 2025-2032, reaching approximately USD 3,334.47 million by 2032.

Artificial Intelligence (AI) in Clinical Trials Market Insights

Geographically, North America is expected to lead the AI in the clinical trial market in 2024, driven by several critical factors. The region’s growing burden of chronic diseases, substantial investments in R&D, and the rising volume of clinical trials contribute significantly to this dominance. Additionally, an increasing number of collaborations and partnerships among pharmaceutical and medical device companies, along with the advancement of sophisticated AI solutions, are accelerating market expansion. These developments are enhancing the ability to manage complex clinical trials efficiently, driving the adoption of AI technologies and supporting the market’s growth in North America throughout the forecast period from 2025 to 2032.

To read more about the latest highlights related to Artificial Intelligence (AI) in Clinical Trials, get a snapshot of the key highlights entailed in the Artificial Intelligence (AI) in Clinical Trials

https://www.delveinsight.com/report-store/ai-in-clinical-trials-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Recent Developments in the Artificial Intelligence (AI) in Clinical Trials Market Report

• In May 2025, Avant Technologies, Inc. (OTCQB: AVAI) and joint venture partner Ainnova Tech, Inc. announced the initiation of acquisition discussions aimed at enhancing their presence in the rapidly growing AI-powered healthcare sector.

• In March 2025, Suvoda introduced Sofia, an AI-driven assistant created to optimize clinical trial management processes. Sofia aids study teams by providing quick access to essential trial data and real-time, intelligent insights. This tool boosts operational efficiency, minimizes manual tasks, and helps teams make faster, data-informed decisions throughout the clinical trial journey.

• In December 2024, ConcertAI and NeoGenomics unveiled CTO-H, an advanced AI-powered software platform designed to enhance research analytics, clinical trial design, and operational efficiency. CTO-H provides an extensive research data ecosystem, offering comprehensive longitudinal patient data, deep biomarker insights, and scalable analytics to support more precise, efficient, and data-driven clinical development processes.

• In June 2024, Lokavant introduced SpectrumTM, the first AI-powered clinical trial feasibility solution aimed at enhancing trial performance throughout the clinical development process. Spectrum enables study teams to forecast, control, and improve trial timelines and expenses in real-time.

• Thus, owing to such developments in the market, rapid growth will be observed in the Artificial Intelligence (AI) in Clinical Trials market during the forecast period

Key Players in the Artificial Intelligence (AI) in Clinical Trials Market

Some of the key market players operating in the Artificial Intelligence (AI) in Clinical Trials market include- TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Unlearn.ai, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, and others.

Which MedTech key players in the Artificial Intelligence (AI) in Clinical Trials market are set to emerge as the trendsetter explore @ Key Artificial Intelligence (AI) in Clinical Trials Companies

https://www.delveinsight.com/sample-request/ai-in-clinical-trials-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Analysis on the Artificial Intelligence (AI) in Clinical Trials Market Landscape

To meet the growing needs of clinical trials, leading companies in the AI in Clinical Trials market are creating advanced AI solutions aimed at improving trial efficiency, optimizing patient recruitment, and enhancing clinical trial design at investigator sites. For example, in April 2023, ConcertAI introduced CTO 2.0, a clinical trial optimization platform that utilizes publicly available data and partner insights to deliver comprehensive site and physician-level trial data. This tool provides key operational metrics and site profiles to evaluate trial performance and site capabilities. Additionally, CTO 2.0 assists sponsors in complying with FDA requirements for inclusive trial outcomes, promoting a shift toward community-based trials with more streamlined and patient-centric designs.

As a result of these advancements, the software segment is projected to experience significant growth throughout the forecast period, contributing to the overall expansion of the AI in the clinical trials market.

Scope of the Artificial Intelligence (AI) in Clinical Trials Market Report

• Coverage: Global

• Study Period: 2022-2032

• Artificial Intelligence (AI) in Clinical Trials Market Segmentation By Product Type: Software and Services

• Artificial Intelligence (AI) in Clinical Trials Market Segmentation By Technology Type: Machine Learning (ML), Natural Language Processing (NLP), and Others

• Artificial Intelligence (AI) in Clinical Trials Market Segmentation By Application Type: Clinical Trial Design & Optimization, Patient Identification & Recruitment, Site Identification & Trial Monitoring, and Others

• Artificial Intelligence (AI) in Clinical Trials Market Segmentation By Therapeutic Area: Oncology, Cardiology, Neurology, Infectious Disease, Immunology, and Others

• Artificial Intelligence (AI) in Clinical Trials Market Segmentation By End-User: Pharmaceutical & Biotechnology Companies and Medical Device Companies

• Artificial Intelligence (AI) in Clinical Trials Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World

• Key Artificial Intelligence (AI) in Clinical Trials Companies: TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Unlearn.ai, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, and others

• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Interested in knowing how the Artificial Intelligence (AI) in Clinical Trials market will grow by 2032? Click to get a snapshot of the Artificial Intelligence (AI) in Clinical Trials Market Analysis

https://www.delveinsight.com/sample-request/ai-in-clinical-trials-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents

1 Artificial Intelligence (AI) in Clinical Trials Market Report Introduction

2 Artificial Intelligence (AI) in Clinical Trials Market Executive summary

3 Regulatory and Patent Analysis

4 Artificial Intelligence (AI) in Clinical Trials Market Key Factors Analysis

5 Porter’s Five Forces Analysis

6 COVID-19 Impact Analysis on Artificial Intelligence (AI) in Clinical Trials Market

7 Artificial Intelligence (AI) in Clinical Trials Market Layout

8 Global Company Share Analysis – Key Artificial Intelligence (AI) in Clinical Trials Companies

9 Company and Product Profiles

10 Project Approach

11 Artificial Intelligence (AI) in Clinical Trials Market Drivers

12 Artificial Intelligence (AI) in Clinical Trials Market Barriers

13 About DelveInsight

Latest Reports by DelveInsight

• Percutaneous Arterial Closure Device Market: https://www.delveinsight.com/report-store/vascular-closure-devices-market

• Transdermal Drug Delivery Devices: https://www.delveinsight.com/report-store/transdermal-drug-delivery-devices-market

• Infusion Pumps Market: https://www.delveinsight.com/report-store/infusion-pumps-market

• Acute Radiation Syndrome Market: https://www.delveinsight.com/report-store/acute-radiation-syndrome-pipeline-insight

• Human Papillomavirus Hpv Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market

• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market

Contact Us

Gaurav Bora

info@delveinsight.com

+14699457679

www.delveinsight.com

Connect With Us at:

LinkedIn | Facebook | Twitter

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.

Source link

Up Next

A robot shows that machines may one day replace human surgeons | Science

Don't Miss

New York Seeks to RAISE the Bar on AI Regulation – Tech & Sourcing @ Morgan Lewis

The Editors

Click to comment

AI Insights

Govt. AI Assessment Ranks States’ Readiness, Adoption Levels

Published

1 hour ago

July 9, 2025

The Editors

An AI readiness assessment released Wednesday by Code for America explores how U.S. state governments are preparing for the AI-powered public-sector transformation and identifies emerging trends within that shift.

Trends highlighted in the analysis include the rise of chief AI officers, investment in training programs, an evolving cybersecurity threat landscape, state-level policymaking, and secure sandbox environments for experimentation.

The Government AI Landscape Assessment explores AI readiness in three areas: leadership and governance, capacity building, and technical infrastructure and capabilities. The resource classifies states’ readiness levels in each of these areas under one of four categories: early, developing, established or advanced. The early classification includes states that have taken the initial steps in AI adoption, while the advanced classification recognizes states with sophisticated capabilities, frameworks and approaches.

States leading in readiness, according to this assessment, are Pennsylvania, New Jersey, and Utah, each of which received two “advanced” classifications and one “established” classification.

Each of these states has prioritized AI readiness. Pennsylvania has been testing and measuring AI for impact, and New Jersey is taking an economy-focused approach to AI and has been an early implementer of AI training. Utah has been an early AI adopter and even recently created an AI policy office that aims to answer societal AI questions.

Overall, in the category of leadership and governance, only three states were classified as advanced. Half, or 25, were classified as established; 16 as developing; and seven as early. Washington, D.C., was included as a state in this assessment. Utah and North Carolina were highlighted for their work in this area.In AI capacity building, four states were classified as advanced, 10 as established, 23 as developing, and 14 as early. New Jersey and Pennsylvania were highlighted for their work here.

In technical infrastructure and capabilities, three states were classified as advanced, 16 as established, 23 as developing, and nine as early. Colorado and Minnesota were highlighted for their work in this.

“This analysis demonstrates what many of us know to be true: states are leading the way when it comes to adopting AI to make government more efficient and effective,” Jenn Thom, Code for America’s senior director of data science, said in a statement.

The assessment was created by reviewing public materials, AI-focused legislation and policy, guidance and reports, news coverage, and direct input.

Debate has arisen recently about whether AI policymaking should occur at the state or federal level, with the consensus largely being that both should have a role in regulation. With the removal of a provision to enact a moratorium on state-level AI regulation from the federal budget bill, states retain the authority to enact policy to guide responsible AI use.

Source link

AI Insights

Microsoft launches $4B artificial intelligence reskilling institute

Published

2 hours ago

July 9, 2025

The Editors

Microsoft unveiled a new initiative Wednesday that’s intended to bring artificial intelligence skills to millions of people around the world.

Microsoft Elevate will spend $4 billion in cash and technology donations to philanthropic, educational, and labor organizations over the next four years, as it seeks to accelerate the proliferation of AI technology.

Microsoft makes the AI tool CoPilot, and is a key partner of OpenAI, the maker of ChatGPT. The company is investing aggressively in the infrastructure needed to power its AI push, pledging to spend $80 billion on data centers this year.

The investments come as Microsoft lays off thousands of employees in in its home state, Washington, and globally.

“ One of the things that has changed the most dramatically about Microsoft is we’ve moved as a company — as our industry has moved as an industry — from one that spent almost every dollar it earned on employing people to what is in fact the greatest capital and infrastructure investment in the history of global infrastructure,” Microsoft President and Vice Chair Brad Smith said at a launch event in Seattle.

In an interview with KUOW, Smith said that restructuring is “ frankly something that should always be hard, but it is something that needs to be done for a company to be successful for many decades and not just a few years.”

Smith said Microsoft Elevate will employ about 300 people, and partner with organizations around the world on a variety of initiatives aimed at increasing AI literacy. The Microsoft Elevate Academy plans to help 20 million people earn AI skilling credentials to be more competitive in an uncertain job market.

“ I think in many ways it gives us the opportunity to reach everybody,” Smith said, “and that includes people who will be using and designing AI in the future, say the future of what computer science education becomes, people who are designing AI systems for businesses, but consumers as well, students and teachers who can use AI to better reach and prepare for helping students.”

The initiative also includes the creation of Microsoft’s AI Economy Institute, a think tank of academics that will study the societal impacts of AI.

The effect generative AI will have on education remains a source of much speculation and debate.

While some educators are embracing the technology, others are struggling to rein in cheating and question whether the technology could undermine the very premise of education as we know it.

Regardless of the ongoing debate, Microsoft has always been at the forefront of bringing technology into the classroom, first with PCs and now AI. The company is betting that the resources it is devoting to Microsoft Elevate will help shape a path forward that allows AI to be more useful than disruptive in education and across the economy.

“ There are many different skills that we’re all going to need to work together to pursue, but I think there’s also a North Star that should guide us,” Smith said. “It’s a North Star that might sound unusual coming from a tech company, but I think it’s a North Star that matters most. We need to use AI to help us think more, not less.”

Source link

AI Insights

Artificial Intelligence and Criminal Exploitation: A New Era of Risk

Published

2 hours ago

July 9, 2025

The Editors

WASHINGTON, D.C. – The House Judiciary Subcommittee on Crime and Federal Government Surveillance will hold a hearing on Wednesday, July 16, 2025, at 10:00 a.m. ET. The hearing, “Artificial Intelligence and Criminal Exploitation: A New Era of Risk,” will examine the growing threat of Artificial Intelligence (AI)-enabled crime, including how criminals are leveraging AI to conduct fraud, identity theft, child exploitation, and other illicit activities. It will also explore the capabilities and limitations of law enforcement in addressing these evolving threats, as well as potential legislative and policy responses to ensure public safety in the age of AI.

WITNESSES:

LTC Andrew Bowne, Former Counsel, Department of the Air Force Artificial Intelligence Accelerator at the Massachusetts Institute of Technology
Ari Redbord, Global Head of Policy, TRM Labs; former Assistant United States Attorney
Zara Perumal, Co-Founder, Overwatch Data; former member, Threat Analysis Department, Google

Source link